[Company Logo Image] Compound validation and profiling in vitro and in vivo
Improved clinical predictability of preclinical studies
Subcutaneous and orthotopic human xenografts
Genetically modified organ specific tumour models
Receptor tyrosine kinase-driven breast cancer model

         Preclinical Concept Validation

Angiogenesis in vivo Model

       

Syngeneic tumour models
Pharmacokinetic studies
  Toxicology (GLP)
  Histology (Frozen Sections and Paraffin Embedded Sections)

                      

Home vivoPharm Search Employment Feedback

Up R&D News Services Management

 

Oncogene-driven syngeneic breast cancer Models
vivoPharm uses a unique technology to replace endogenous epithelium in organs, in particular in the mammary gland, with epithelium infected with an virus containing an oncogene of interest. This allows tailoring and adapting tumour models to the clinical situation, where more and more specific “drivers” (oncogenes) of certain tumours are characterised and used as prognostic markers. It is well accepted that such "drivers" (oncogenes) are excellent targets for anticancer therapy.
vivoPharm's IP in organ specific target-driven tumour models will provide  tumour models
likely possessing much more predictive power for the clinical outcome than other conventional tumour models. Pilot studies were already undertaken  in 2002.

 

Prostate cancer Models

please visit again to see more details in this section

 

   

Send mail to webmaster@vivopharm.com with questions or comments about this web site.
Last modified: 18-Dec-2003